OrganoPlate Graft SIGNED
Organ-on-a-Chip technology for in vitro grafting and vascularisation of 3D tissues
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0OrganoPlate Graft project word cloud
Explore the words cloud of the OrganoPlate Graft project. It provides you a very rough idea of what is the project "OrganoPlate Graft" about.
Project "OrganoPlate Graft" data sheet
The following table provides information about the project.
| Coordinator |
MIMETAS BV
Organization address contact info |
| Coordinator Country | Netherlands [NL] |
| Total cost | 3˙014˙718 € |
| EC max contribution | 2˙110˙303 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-2 |
| Funding Scheme | SME-2 |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-03-01 to 2021-02-28 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | MIMETAS BV | NL (Leiden) | coordinator | 2˙110˙303.00 |
Map
Project objective
PROBLEM – The drug development cycle, from basic research to testing efficacy, toxicity, and safety of new therapeutics, is largely depending on animal models. However animal biology and pathology differ from human biology at crucial points. The sector is aware of the significant complications in their usage, but lacks better alternatives. Highly advanced technology exists for the culture of cell systems, organs, tumors, etc. outside the body (‘in vitro’). However, the existing culture models lack functional blood vessels – a vital structure inside the body (‘in vivo’). There is a great unmet need for better models of human biology, to speed up both basic research on human biology as well as the development of novel, much needed therapeutic solutions. SOLUTION – OrganoPlate Graft involves the development to market readiness of the first high-throughput in vitro culture method for vascularized tissue that is unrivalled by the available in vitro options. An extensive proof of concept (PoC) for this method has been obtained. The new product will be launched within 6-months post-project and, for the first time, allow for the study and manipulation of human tissues with functional human vascularization. COMPANY – Founded in 2013, the Dutch SME MIMETAS was the first party to commercially exploit organ-on-a-chip technology that enables accurately controlled and monitored in vitro cultivation 3D ‘mini-organs’. MIMETAS currently employs > 60 professionals, generates year-on year multi-million revenues, and is projected to be profitable as of 2020. RESULTS – The results of the 2-year OrganoPlate Graft project will empower Users by aiding them to grow tissues with human vascularization in vitro – enabling the replacement of a wealth of animal experiments and the design of completely novel experiments in research, development and clinical settings. OrganoPlate Graft will cost €3M, employ 10 new FTEs, and is projected to add 40 FTE and >€50M annual revenues to MIMETAS by 2022.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ORGANOPLATE GRAFT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ORGANOPLATE GRAFT" are provided by the European Opendata Portal: CORDIS opendata.